Immunology: LAG-3 Agonist Shows Clinical Efficacy for the First Time (T-Cell Suppression)
Immutep has successfully completed human trials using the KLH neoantigen model. The drug IMP761 dose-dependently reduced inflammation and T-lymphocyte activity, confirming that targeting the LAG-3 receptor can effectively treat autoimmune diseases without the side effects of existing immunosuppressants.
An analytical article from an insider who sees behind the modest news of passing Phase I not just "another antibody candidate," but the first step toward a paradigm shift in treating autoimmune diseases — and the beginning of a bloody battle for a market dominated by Humira and its successors.
Headline: The LAG-3 Turnaround: Why the Modest Agonist IMP761 Is Scarier for AbbVie Than Any Biosimilar
Introduction
While investors and analysts are buzzing over the latest GLP-1 data or CAR-T successes, at the EULAR 2026 congress in London, an event occurred that I call a "silent tsunami." The Australian-French company Immutep (ASX: IMM, NASDAQ: IMMP) reported the completion of the first phase of its monoclonal antibody IMP761. Formally — just news of successful safety. Informally — the first clinical case in history where we pressed the immune brake pedal not with a blunt hammer (methotrexate, steroids), but with an elegant key that activates the natural regulatory receptor LAG-3.
Over the ten years of blockbusters like Keytruda (pembrolizumab), we got used to LAG-3 being a target for blockade to rev up T-cells against cancer. In 2022, the FDA approved the first dual blocker (Opdualag from BMS). And then Immutep says: we made an agonist. We are not unlocking the brake; we are pressing the pedal even harder to silence chronic inflammation.
Dr. Frederic Triebel (CSO Immutep), who originally discovered the LAG-3 gene back in the 1990s, now states that IMP761 is a "targeted therapy for the root cause of autoimmunity." This concerns rheumatoid arthritis (RA), multiple sclerosis, type 1 diabetes. The market is tens of billions of dollars. But there are nuances that press releases keep quiet about.
[The Essence]: What Is Really Happening
We are used to the dual nature of immune checkpoints: LAG-3, PD-1, CTLA-4 work like a thermostat. In cancer, the thermostat is stuck on "off" (T-cells are asleep), and antagonists (blockers) turn them back on. In autoimmunity, the thermostat is stuck on "on" (T-cells attack own tissues), and agonists are needed to engage the braking mechanism.
What is the genius of IMP761? Imagine LAG-3 as a lock on a door that only opens if the T-cell has constant antigenic stimulation. That is, healthy, "resting" T-cells barely express LAG-3. But pathological, chronically activated T-cells that destroy joints in RA or myelin in MS — they "hang" on LAG-3 constantly. IMP761, binding to this receptor, sends a signal inside the cell: "Stop, stand down." This is called "restoring peripheral tolerance."
The main number you won't see in headlines is p = 0.029 for reduction of skin perfusion at a dose of 7 mg/kg in the KLH model (keyhole limpet hemocyanin). This is a statistically significant suppression of the T-cell response to a foreign antigen in healthy volunteers. In other words, they proved the drug works as an immunosuppressant in vivo in a controlled, double-blind, placebo-controlled study. This is not "we see an effect in a test tube." This is "we see significantly less skin swelling in a living person."
Moreover, the pharmacokinetics support dosing every 4 weeks. For a chronic patient, this is a game-changer: inject once a month and forget about pills with hepatotoxicity. The press release also states that at the highest tested dose level, suppression of T-cell infiltration into the skin on day 10 after rechallenge with the neoantigen reached 80%.
[Timeline and Context]
To understand why this news took off now, you had to watch the calendar and stock market summaries of recent months.
July 2024: Immutep signs an agreement with the Centre for Human Drug Research (CHDR) in Leiden, Netherlands, to conduct the first clinical study of IMP761. CHDR will use its unique KLH challenge model.
August 2024: The first volunteer receives a dose of IMP761 in the Phase I study.
June 2025: Immutep announces positive preliminary data: at the highest dose level, no treatment-related adverse events, and pharmacodynamic data show 80% suppression of T-cell infiltration.
February 2026: In a corporate presentation, Immutep reports that cash (A$129.3 million) will last at least until Q2 2027, and indicates the potential for a strategic partnership for IMP761.
June 3-5, 2026, EULAR 2026, London: Immutep presents a poster. Data: "statistically significant pharmacodynamic activity at 7 mg/kg (p=0.029)." Silence in mainstream media. But within the rheumatology community — shock. The KLH protocol is the "gold standard" for testing immunomodulators in healthy people. They showed a dose-dependent effect.
Countdown: It is now June 2026, enrollment for the MAD (multiple ascending dose) part is ongoing. Completion is in the second half of 2026. If MAD shows the same safety profile (and this is not steroids, not methotrexate with its liver cirrhosis), then in 2027 we will see the launch of Phase II in real patients with rheumatoid arthritis.
[Who Wins and Who Loses]
Biggest loser: TNF-alpha blockers (Humira/Amjevita, Enbrel, Remicade) and JAK inhibitors.
The anti-TNF therapy market is still tens of billions of dollars annually. But they have drawbacks: they hit a broad front of cytokines, increasing the risk of infections (tuberculosis, fungal) and lymphomas. IMP761 acts on the source itself — the activated T-cell. If it works, the therapeutic window becomes wider. Patients will stop fearing injections and getting pneumonia. Shares of AbbVie (Humira) and Pfizer (Xeljanz) could correct upon announcement of positive Phase II data.
Winner: The field for bispecifics and CAR-Treg (Treg therapy).
A non-obvious insight. The LAG-3 agonist combines well with low-dose IL-2 or Treg therapy. If you transplant regulatory T-cells (Tregs) into a person, you need them to survive and suppress aggression. IMP761 could become an ideal "combination partner." No one is talking about this openly yet, but preclinical data on juvenile idiopathic arthritis show: IMP761 reduces a broad spectrum of effector cytokines (IFNy, IL-4, TNFa) in cocultures with synoviocytes.
Winner: Immutep (ASX: IMM, NASDAQ: IMMP) and its shareholders.
The company received clear validation of its platform. They have not only IMP761 but also eftilagimod alpha (efti — soluble LAG-3) in oncology, which is in Phase III for non-small cell lung cancer in collaboration with Merck & Co. Now their portfolio is balanced: oncology + autoimmunity. This increases interest from potential buyers.
Loser: Old immunosuppressants (methotrexate, azathioprine).
These drugs act like a sledgehammer, suppressing all immunity — both bad and good. IMP761 has a chance to become the first "smart" immunosuppressant with minimal systemic toxicity.
[What the Media Aren't Saying]
Three things you should know but won't make it into glossy headlines.
1. The "Dose Shift" Problem (Therapeutic Window).
Phase I showed safety in healthy people. But a healthy person does not have autoimmune aggression. In Phase II, when we give IMP761 to an RA patient, paradoxical effects may arise. The fact is that LAG-3 is expressed not only on effector T-cells but also on Tregs (regulatory). If we accidentally suppress Tregs (which are needed to keep immunity in check), we could get enhanced autoimmunity or even induction of new diseases. Immutep skirts this topic in press releases, citing high specificity for "activated" cells, but in reality, the ratio of Treg/Teff stimulation in synovial fluid of the joint is an unknown quantity. This is the "black swan" of the program.
2. Immunogenicity of the Human Antibody and Patent Protection.
Is IMP761 a fully human antibody? Reports state it is a "first-in-class immunosuppressive LAG-3 agonist antibody." But any biological agonists that force a receptor to "flicker" in an active state risk inducing anti-idiotypic antibodies. The body might decide: "aha, this protein keeps yanking my receptor, let's kill it." The immunogenicity profile in Phase I was good, but on repeated doses in Phase II (MAD), problems may surface. On the other hand, Immutep has already obtained a US patent for IMP761, which blocks competitors from creating "me-too" agonists for years to come.
3. Financial "Hanging" and the Need for a Partner.
Immutep has cash until Q2 2027, but conducting Phase II for RA (which involves thousands of patients, expensive logistics) may require additional funding. At EULAR 2026, they presented data precisely to sell a license. CEO Mark Voigt directly mentions a "potential strategic partnership." If a deal does not materialize in the next 6-9 months, the company may be forced to conduct dilutive financing (secondary offering), which would hit shareholders.
[Forecast: Next 30 Days and 90 Days]
Next 30 days (July 2026):
Analysts at Jefferies and Leerink Partners, specializing in small biotechs, will release their first analyses of the EULAR data. "Buy" ratings with target prices 30-50% above current levels are likely (IMMP is currently trading around $1.5-2). Expect increased volatility, as hedge funds with short positions may try to drive down the price, citing "small sample size" and "lack of patient data."
Next 90 days (September-October 2026):
The key moment is the publication of full results from the Multiple Ascending Dose (MAD) study in the second half of 2026. If these data confirm safety upon repeated administration and absence of increasing immunogenicity, it will trigger a licensing agreement. Most likely partners:
- AbbVie — they critically need to replace falling sales of Humira (which is losing patent protection) and Skyrizi with something fundamentally new. A LAG-3 agonist fits perfectly into their rheumatology portfolio.
- Novartis — they have Cosentyx (secukinumab), but it only hits IL-17. A LAG-3 agonist could become a "first-line" therapy for a broader range of autoimmune diseases.
Main insider forecast:
I expect a deal to be signed by the end of 2026 or early 2027. Amount: $300-500 million upfront + royalties up to $2 billion plus double-digit percentages of sales. This would save Immutep as an independent company and give them resources to complete Phase III in oncology.
But there is an alternative scenario: if MAD data disappoint (e.g., a signal of hepatotoxicity or neutralizing antibodies appears), IMMP shares could fall 40-50%, and the company could become a target for a hostile takeover at a bargain price.
The stakes are high. But now, looking at the clean data of p=0.029 and 80% T-cell suppression, I bet on the bulls. Finally, we have learned to brake immunity without killing it. The game is on.
— Editorial Team
